Bedrocan Bankruptcy: The Dutch Government Under Pressure

The bankruptcy of Bedrocan, one of Europe’s leading producers of medical cannabis, has sparked a political controversy in the Netherlands and raised concerns about patients’ access to essential treatments in several European countries.

As efforts to turn the company around intensify, the founder Tjalling Erkelens accused the Dutch government of withholding crucial information about the circumstances surrounding the bankruptcy.

For her part, the Minister of Health Sophie Hermans confirmed delays in the passage of the planned cannabis legislation and acknowledged that disruptions in the supply of medications could occur in 2027.

Bedrocan's founder disputes the Dutch government's account

Declared bankrupt on October 7, 2026, Bedrocan Netherlands and Bedrocan International were placed in insolvency proceedings following mounting financial difficulties. Tjalling Erkelens argues that the government’s handling of the situation directly contributed to the company’s collapse.

In a public statement reported by CannabisIndustrie.nl, he identified four alleged inconsistencies between the minister's parliamentary letter dated November 6 and the bankruptcy report prepared by the bankruptcy trustees.

According to Erkelens, the Dutch Office for Medical Cannabis (BMC) refused to provide financial guarantees that could have secured emergency financing from Rabobank. He also claims that government officials turned away potential buyers and scaled back their purchase commitments after initially supporting Bedrocan’s expansion in Emmeloord.

Another dispute, dating back to 2023, involved cannabis stored outside of freezing facilities, which the authorities considered to be potentially spoiled.

The government disputes the company's interpretation, arguing that financial assistance would have exposed taxpayers to unacceptable risks.

A potential fresh start under new ownership

Despite the bankruptcy, Bedrocan could resume operations through a new legal entity, according to Business of Cannabis. The court-appointed receivers have selected a potential acquisition proposal, although financing and court approval are still pending. The restructuring could preserve part of the company’s operations in the Netherlands and Denmark, with a primary focus on international exports.

However, job prospects remain limited. Of the 69 employees laid off following the bankruptcy, no more than about ten could, according to some sources, join the company that will take over.

On the other hand, Becanex, which was already working with Bedrocan on its THC concentrates, acquired Bedrocan’s Canadian shares and intellectual property for €200,000. The Canadian operation could eventually manufacture Sorrow, a CBD-dominant product used by patients with severe epilepsy.

However, any resumption of production would take several months before a new supply of the product becomes available.

Patients Facing Supply Uncertainty in 2027

The most pressing concern is the availability of standardized medical cannabis products, in particular the Sorrow, used to treat certain forms of drug-resistant epilepsy. According to the Dutch Ministry of Health, existing stocks of Bedrobinol could run out by the beginning of the second quarter of 2027, while Bedrolite's inventory could last until the beginning of the third quarter.

Other varieties, including Bedrocan, Bediol and Bedica, are expected to remain available until around the middle of the third quarter. The government plans to launch a new European tender process in December 2026, select a supplier in May 2027, and begin deliveries in September.

This schedule could lead to a supply shortage, particularly for patients whose treatment cannot be easily replaced.

The situation is particularly delicate in the United Kingdom, where a small number of patients rely on Bedrolite to manage severe epileptic seizures. Fortunately, no French patients will be affected!

Dutch Cannabis Reform Delayed

The bankruptcy also disrupted the Dutch bill to reform the Opium Act, aimed at ending the government’s exclusive control over the medical cannabis trade. Originally scheduled for July 1, 2028, the implementation of this legislation has now been postponed indefinitely.

Minister Hermans attributes this delay in part to administrative constraints related to Bedrocan's insolvency.

The controversy will come before Parliament again on November 26, at which time lawmakers are expected to consider bankruptcy, legal remedies, and the consequences for patients.